Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and ComedicationsCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52022-06-07186OAAI
Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug InteractionsANNALS OF INTERNAL MEDICINEIF15.22022-05-0140OA
Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIVJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62021-11-1712OAAI
Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic DevelopmentCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52020-11-2118OAAI
Prescribing in COVID-19 patients: Should we take into account inflammation?BRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32020-08-200OAAI
Safety perspectives on presently considered drugs for the treatment of COVID-19目前考虑用于治疗新型冠状病毒肺炎的药物的安全性观点BRITISH JOURNAL OF PHARMACOLOGYIF7.72020-08-1315OAAI
Drug interactions: a review of the unseen danger of experimental COVID-19 therapiesJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62020-08-0431OAAI
The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeuticsJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62020-06-262OAAI
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effectJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62020-06-1748OAAI
Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human PharmacokineticsCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52020-06-1497OAAI
COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactionsBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32020-05-1320OAAI
Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV TherapyOPEN FORUM INFECTIOUS DISEASESIF3.82020-02-0318OAAI
Drug-drug interactions in HCV therapy: Still relevant for clinical practice?JOURNAL OF HEPATOLOGYIF332019-04-010PREAI
Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoringJOURNAL OF HEPATOLOGYIF332019-03-0111OAAI
Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic ModelingJOURNAL OF INFECTIOUS DISEASESIF4.52018-12-1946OA
Therapeutic Drug Monitoring of DAAs overcomes contraindications against anti-epileptics in HCV treatment (HepNed003)JOURNAL OF HEPATOLOGYIF332018-04-010PREAI
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medicationsBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32018-02-212OAAI
Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ARTJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62018-01-2216OAAI
Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugsJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62016-12-2016OAAI
Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessmentLANCET HIVIF132016-12-0180OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向